Investing in visionary founders, transformational technology and emergent ecosystems for a new world.

Innovation Endeavors
Innovation Endeavors
66
companies
1,312
Jobs
Showing 66 companies
Innovation Endeavors is an early-stage venture capital firm that invests in mission-driven founders, transformational technologies, and emergent ecosystems. The firm’s central investment thesis, the Super Evolution, combines data, leading-edge computation, and advanced engineering to transform a range of industries including agriculture, supply chain, the life sciences, transportation and more. Its investments include AlphaSense, Astra, Color, Blue River Technology, Eikon Therapeutics, Fabric, Formlabs, Freenome, Planet, Rebellion, Replica, SoFi, Uber, Upstart, Vicarious Surgical, and more. For more information, visit www.InnovationEndeavors.com.
Afresh
Afresh
7 jobs
At Afresh, we’re solving the big problems around food waste and the fresh food supply chain--focusing first on grocery. We use cutting-edge AI (we’ve been published in ICML!) combined with thoughtful design to enhance decision-making and optimize store workflows. The results are powerful: in live deployments in grocery stores, we have demonstrated the potential to double profits and reduce food waste by 50%+!
AlphaSense
AlphaSense
62 jobs
AlphaSense is an AI-powered business insights platform that is transforming the way companies uncover insights and make critical decisions.
Anyword
Anyword
6 jobs
Anyword is a natural language generation platform that helps marketers tailor their messages to their ideal audience. Our platform uses a model trained on millions of marketing messages, coupled with your historical data to help you create expert-level messages across channels and formats. Anyword powers the world’s top marketers, including The New York Times, PetCareRx, NBA, Red Bull, Ted Baker, and others.
Aro Homes
Aro Homes
6 jobs
Aro Homes is a new company on a mission to redefine residential construction by building better, more sustainable homes faster and more efficiently. We believe that home construction should be better for the planet and deliver better homes for the people who live in them. When we look at the massive US residential construction industry, we see tremendous opportunities for fundamental improvement around end-product quality, speed, waste, cost, environmental impact and more. We are a team of passionate, capable experts across Engineering, Construction, Design, Product Management, and Manufacturing who believe the time has come to improve this industry so it’s better for people and the planet. We are funded by world class investors who care about transforming industries for the better, including Eric Schmidt’s Innovation Endeavors. If you care deeply about doing something good in the world, working with smart, passionate people and tackling hard problems, then you should talk with us.
At Atom Computing, we’re our customers’ biggest fans on the journey of discovery. That’s why we’re obsessed with creating the world’s most scalable and reliable quantum computers—giving them the power to develop breakthroughs that change the world.
Authomize
Authomize
1 jobs
Authomize continuously monitors the organizations' identities, access privileges, assets, and activities, to secure all apps and cloud services.​ We seamlessly connect to organizations' apps and cloud services, collects all relevant information to graph's data-lake to help organizations' security teams achieve Zero Trust. Authomize provides organizations with comprehensive observability, actionable insights, and remediation automation, enabling adherence to security and compliance requirements.
Beamr is a global video software technology leader in H.264 and HEVC encoding and optimization solutions. The company was founded in 2009 by a team of leading image science experts and is backed by Verizon, Disruptive, and Eric Schmidt's fund, Innovation Endeavors. Beamr has more than 80 employees located in Palo Alto California, Tel Aviv Israel, and St. Petersburg Russia.
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.
Bolt is a materials company that invents and scales materials that put the planet on a path towards a better future. Biofabricated silk fibers MicrosilkTM - based on proteins found in nature, produced using Bolt Threads proprietary technology and revolutionary bioengineering concepts. Next-generation of performance fibers, fabrics and luxury products that represent cutting-edge technology in science, while raising the bar for quality, performance, and design.
Canvas is a construction robotics company that uses machine learning to install drywall at construction sites. It delivers unrivaled quality, speed, and predictability by putting robots in the hands of skilled workers. Through its novel approach, they have reinvented drywall finishing to give projects better outcomes.
Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.